|Videos|September 3, 2022
PD-L1 Expression and IO Therapy in Lung and Breast Cancer
A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.
Episodes in this series
Related to this article
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.
Nirav N. Shah, MD, MSHP, discusses bexobrutideg and what the BTK degrader could bring to chronic lymphocytic leukemia management.
Promising data for zenocutuzumab in patients with advanced NRG1-positive cholangiocarcinoma were shown according to researchers at Dana-Farber.
OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development.
Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
The FDA gave a CRL to the NDA seeking the approval of Orviglance for use in the detection of liver metastases in patients with severe kidney impairment.
Trending on OncLive
1
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
2
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
3
AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design
4
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
5